Listen to the Full Podcast Equity Mates Investing co-hosts, Bryce and Ren, interview Imricor Medical Systems (ASX: IMR) CEO, Steve Wedan. In this podcast, Steve talks through Imricor, how he first came across the idea and what has been the founding story to date. Listen to the full podcast here or on Apple.
1 August 2023 – Minneapolis, MN United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR), the global leader in real-time iCMR cardiac ablation products, is pleased to announce it has received approval from the Medical Ethics Review Committee, Leiden The Hague Delft (METC LDD) to begin the VISABL-VT trial at Haga Hospital in The Hague, Netherlands. The VISABL-VT trial is a prospective, single-arm, multi-centre investigation of the safety and efficacy of radiofrequency (RF) ablation of ventricular tachycardia (VT) associated with ischemic cardiomyopathy performed with the Vision-MR Ablation Catheter 2.0 in the iCMR environment. The study calls for treating 64 patients and includes a six-month follow-up for each patient. The study is intended to support CE mark certification of the Vision-MR Ablation Catheter 2.0 for treating VT. The first patient to be enrolled in VISABL-VT is identified, and the first procedure is expected to take place in mid-August, upon the return of physicians and medical staff from summer holiday. Imricor’s Chair and CEO, Steve Wedan, commented: “This is an extraordinary milestone for Imricor. “Since founding the Company 17 years ago, the goal has always been to develop technology that enables complex cardiac arrhythmias like ventricular tachycardia (or VT) to be treated utilising real-time 3D MRI (which we call interventional cardiac magnetic resonance, or iCMR) for guidance. We believe real-time 3D MRI imaging can add tremendous value to VT ablations in terms of effectiveness, time savings, and cost – all in an environment that is free of ionising radiation. “Imricor continues to do what no one else has ever done before, and virtually everyone in the Company has worked tirelessly to make this extraordinary milestone possible. I want to especially acknowledge the clinical and regulatory teams led by our Director of Clinical Research, Dr. Katherine Lindborg, PhD, and our VP of Regulatory and Quality, Jennifer Weisz.”
31 July 2023 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in real-time iCMR cardiac ablation products, is pleased to announce it has entered into a Distribution Agreement with Al Faisaliah Medical Systems (FMS) Subsidiary of Tibbiyah Holding Company, a prominent distributor in the Kingdom of Saudi Arabia (KSA). Under the terms of this 5-year agreement, FMS will be the exclusive distributor of Imricor’s products in KSA, a country which performs nearly 50,000 cardiac ablation procedures annually. FMS will also obtain and maintain all required regulatory approvals to import and sell Imricor products in Saudi Arabia, a process that is expected to be completed in Q3 2023, with product launch in KSA starting October 1st, 2023. Imricor expects procedures to be completed in the first 12-months of the partnership. This marks a major achievement for Imricor as it enters a new geographical area, bringing the first and only iCMR family of products to healthcare professionals and patients in KSA. Imricor intends to continue to expand into the Middle East region with additional countries expected over time. Imricor’s collaboration with FMS underscores its commitment to expansion and continued growth in strategic markets. Founded in 1973, FMS has an impressive track record of success with more than a billion dollars in revenue annually. FMS brings a wealth of expertise and a robust distribution network to ensure seamless market penetration for Imricor’s technology in KSA. Imricor’s Chair and CEO, Steve Wedan, said: “We are extremely pleased to partner with one of the leading medical device distributors in the Kingdom of Saudi Arabia. FMS is working with multiple hospitals to establish state of the art cardiology centres throughout KSA, and now is a great time for Imricor’s technology to be introduced at these sites, where the iCMR labs will be dedicated cardiology-owned facilities. “As I’ve said in the past, our sales efforts all over the world are focused on establishing dedicated iCMR facilities, and our partnership with FMS is well aligned with this strategic goal, while it also further grows our geographic footprint. FMS, Subsidiary of Tibbiyah Holding Company CEO, Alaa Ameen, said: “With our partnership with Imricor, we’re extremely excited in bringing the unique Imricor iCMR technology to Saudi cardiac Centres that aim to be worldwide leader in patient outcomes. I’m confident that this state-of-the-art technology will add value to patient outcomes and meet the expectations of the Saudi cardiac Centres. In Tibbiyah Holding Company, we are doing our best to align our customers goal with Saudi Vision 2030 to establish the best cardiac Centres in the Middle east region.”
Minneapolis MN (July 11 2023) – Imricor Medical Systems, Inc. (ASX:IMR) Imricor, the global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation products, is pleased announce it has entered into a non-exclusive software distribution agreement with ADAS 3D Medical S.L. (ADAS 3D Medical) a leading developer of imaging solutions for the electrophysiology (EP) market.
April 11 – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR), the global leader in real-time iCMR cardiac ablation products, is pleased to announce that the University Hospital Lausanne (CHUV) in Lausanne, Switzerland has submitted a purchase order to Imricor for the capital equipment required to fit out the CHUV’s new iCMR lab, scheduled to open this July.
At the Helios Klinikum Berlin-Buch, catheter ablation was performed using a cardiac MRI. For the first time, a team of cardiologists has paired the standard procedure of catheter ablation with a cardiac MRI. In the future, this new method promises to improve the treatment of complex cardiac arrhythmias through real-time imaging and more precise treatment of heart tissue. The head of the Heart Rhythm Center Berlin/Brandenburg at the Helios Klinikum Berlin-Buch Dr. med. Michael Wiedemann explains the innovative process in an interview.
22 September 2022 – Minneapolis, MN United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR), the global leader in real-time iCMR cardiac ablation products, is pleased to announce that the Company has submitted for approval to commence a real-time iCMR-guided ventricular tachycardia (VT) ablation clinical trial.
11 August 2022 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in realtime interventional cardiac magnetic resonance (iCMR) cardiac ablation products, is pleased to announce it has entered into two new agreements with Siemens Healthineers that together provide Imricor the ability to deploy the Company’s new 3D mapping system on the Siemens Healthineers Magnetic Resonance Imaging (MRI) platform.
31 March 2022 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in Realtime iCMR cardiac ablation products, is pleased to announce it has entered into a Development Agreement with Mammendorfer Institut für Physik und Medizin GmbH (MIPM), a leading developer and manufacturer of MRI-compatible medical devices, including an MRI-compatible external cardioverter defibrillator. MIPM is headquartered in Mammendorf, Germany. Performing cardiac ablation of complex arrythmia, such as VT, requires an external cardioverter defibrillator. MIPM has developed such a system. Imricor’s Vice President of Marketing and Business Development, Nick Twohy, said: “We are thrilled to be aligned with a world leader in providing MRI-compatible devices. MIPM’s defibrillator and technology are critical to the success of performing complex iCMR ablations.” Under the terms of the agreement, Imricor and MIPM will collaborate on product development and clinical trials, including Imricor’s upcoming trial for expanded indications to VT ablation procedures in the iCMR. Andreas Klement, Vice President, MIPM, stated, “MIPM is very happy about the cooperation with Imricor and expects a long-term and fruitful cooperation in this innovative field of electrophysiological examinations and ablation procedures in the MR-Environment.”